These Analysts Boost Their Forecasts On GoodRx Holdings After Q2 Results

GoodRx Holdings Inc GDRX reported better-than-expected second-quarter financial results.

GoodRx Holdings reported quarterly sales of $189.7 million, down 1% Y/Y, beating the consensus of $186.82 million and the management guidance of $185-$188 million. Adjusted EPS of $0.07, beat the consensus of $0.06.

GoodRx revised FY23 sales guidance to $750- $760 million, compared to prior guidance of $750-$775 million and consensus of $762.25 million.

GoodRx shares gained 7.2% to trade at $8.52 on Thursday.

These analysts made changes to their price targets on GoodRx following earnings announcement.

• Wells Fargo raised the price target on GoodRx from $6 to $7. Wells Fargo analyst Stan Berenshteyn maintained an Equal-Weight rating.
• RBC Capital increased the price target on GoodRx from $6 to $8. RBC Capital analyst Sean Dodge maintained a Sector Perform rating on the stock.
• Credit Suisse increased GoodRx price target from $7 to $8. Credit Suisse analyst Jonathan Yong maintained a Neutral rating.
• Goldman Sachs increased GoodRx price target from $6.25 to $7. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating.
• Evercore ISI Group increased GoodRx price target from $7 to $10. Evercore ISI Group analyst Mark Mahaney maintained an In-Line rating.

Check This Out: Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday